Skip to main content
Erschienen in: Pituitary 2/2009

01.06.2009

The effects of hyperprolactinemia on bone and fat

verfasst von: Amal Shibli-Rahhal, Janet Schlechte

Erschienen in: Pituitary | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that prolactin may also be a modulator of body composition and body weight. It is not known whether hyperprolactinemia associated weight gain is due to stimulation of lipogenesis or due to disruption of central nervous system dopaminergic tone. Hyperprolactinemia is also associated with insulin resistance and endothelial dysfunction which may improve after normalization of prolactin. The clinical significance of these findings and the precise role of prolactin in regulation of weight and metabolism remain to be elucidated.
Literatur
3.
Zurück zum Zitat Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303:1511–1514, MedlinePubMedCrossRef Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303:1511–1514, MedlinePubMedCrossRef
4.
Zurück zum Zitat Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56:1120–1123, MedlinePubMed Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56:1120–1123, MedlinePubMed
5.
Zurück zum Zitat Koppelman MC, Kurtz DW, Morrish KA et al (1984) Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59:1050–1053, MedlinePubMed Koppelman MC, Kurtz DW, Morrish KA et al (1984) Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59:1050–1053, MedlinePubMed
7.
Zurück zum Zitat Caraceni MP, Corghi E, Ortolani S, Casazza S, D’Alberton A, Motta T (1985) Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37:687–689, Medline. doi:10.1007/BF02554932 PubMedCrossRef Caraceni MP, Corghi E, Ortolani S, Casazza S, D’Alberton A, Motta T (1985) Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37:687–689, Medline. doi:10.​1007/​BF02554932 PubMedCrossRef
8.
Zurück zum Zitat Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542–546, MedlinePubMedCrossRef Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542–546, MedlinePubMedCrossRef
9.
Zurück zum Zitat Greenspan SL, Neer RM, Ridgway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777–782, MedlinePubMed Greenspan SL, Neer RM, Ridgway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777–782, MedlinePubMed
10.
Zurück zum Zitat Schlechte J, el-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021–1026, MedlinePubMed Schlechte J, el-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021–1026, MedlinePubMed
11.
Zurück zum Zitat Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol (Oxf) 28:1–6 Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol (Oxf) 28:1–6
12.
Zurück zum Zitat Nyström E, Leman J, Lundberg PA et al (1988) Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 29:214–217, MedlinePubMedCrossRef Nyström E, Leman J, Lundberg PA et al (1988) Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 29:214–217, MedlinePubMedCrossRef
13.
Zurück zum Zitat Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124–130, MedlinePubMed Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124–130, MedlinePubMed
14.
Zurück zum Zitat Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526–531, MedlinePubMed Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526–531, MedlinePubMed
15.
Zurück zum Zitat Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G (1990) Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13:419–422, MedlinePubMed Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G (1990) Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13:419–422, MedlinePubMed
16.
Zurück zum Zitat Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75:692–697, Medline. doi:10.1210/jc.75.3.692 PubMedCrossRef Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75:692–697, Medline. doi:10.​1210/​jc.​75.​3.​692 PubMedCrossRef
17.
18.
Zurück zum Zitat Kayath MJ, Lengyel AM, Vieira JG (1993) Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 26:933–941, MedlinePubMed Kayath MJ, Lengyel AM, Vieira JG (1993) Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 26:933–941, MedlinePubMed
19.
20.
21.
Zurück zum Zitat Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52:319–327 Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52:319–327
22.
Zurück zum Zitat Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28:12–17, MedlinePubMed Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28:12–17, MedlinePubMed
24.
Zurück zum Zitat Bikle DD, Spencer EM, Burke WH, Rost CR (1980) Prolactin but not growth hormone stimulates 1,25-dihydroxyvitamin D3 production by chick renal preparations in vitro. Endocrinology 107:81–84, MedlinePubMed Bikle DD, Spencer EM, Burke WH, Rost CR (1980) Prolactin but not growth hormone stimulates 1,25-dihydroxyvitamin D3 production by chick renal preparations in vitro. Endocrinology 107:81–84, MedlinePubMed
27.
28.
Zurück zum Zitat Kumar R, Abboud CF, Riggs BL (1980) The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc 55:51–53, MedlinePubMed Kumar R, Abboud CF, Riggs BL (1980) The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc 55:51–53, MedlinePubMed
29.
Zurück zum Zitat Adams ND, Garthwaite TL, Gray RW, Hagen TC, Lemann J Jr (1979) The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans. J Clin Endocrinol Metab 49:628–630, MedlinePubMed Adams ND, Garthwaite TL, Gray RW, Hagen TC, Lemann J Jr (1979) The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans. J Clin Endocrinol Metab 49:628–630, MedlinePubMed
30.
Zurück zum Zitat Brown DJ, Spanos E, MacIntyre I (1980) Role of pituitary hormones in regulating renal vitamin D metabolism in man. BMJ 280:277–278, MedlinePubMedCrossRef Brown DJ, Spanos E, MacIntyre I (1980) Role of pituitary hormones in regulating renal vitamin D metabolism in man. BMJ 280:277–278, MedlinePubMedCrossRef
31.
Zurück zum Zitat Genant HK, Cann CE, Ettinger B, Gordon GS (1982) Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699–705, MedlinePubMed Genant HK, Cann CE, Ettinger B, Gordon GS (1982) Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699–705, MedlinePubMed
32.
Zurück zum Zitat Steinberg KK, Freni-Titulaer LW, DePuey EG et al (1989) Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533–539, MedlinePubMed Steinberg KK, Freni-Titulaer LW, DePuey EG et al (1989) Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533–539, MedlinePubMed
33.
Zurück zum Zitat Warren MP, Brooks-Gunn J, Fox RP, Lancelot C, Newman D, Hamilton WG (1991) Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab 72:847–853, MedlinePubMed Warren MP, Brooks-Gunn J, Fox RP, Lancelot C, Newman D, Hamilton WG (1991) Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab 72:847–853, MedlinePubMed
34.
Zurück zum Zitat Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78:996–1001, MedlinePubMed Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78:996–1001, MedlinePubMed
35.
Zurück zum Zitat Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R (1991) Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 72:602–606, MedlinePubMed Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R (1991) Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 72:602–606, MedlinePubMed
36.
37.
38.
40.
Zurück zum Zitat Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol (Endocrinol Metab. 27) 264:E986–E992 Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol (Endocrinol Metab. 27) 264:E986–E992
41.
Zurück zum Zitat Galluzi F, Salti R, Stagi S, La Cauza F, Chiarelli F (2005) Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab 18:921–924, Medline Galluzi F, Salti R, Stagi S, La Cauza F, Chiarelli F (2005) Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab 18:921–924, Medline
42.
Zurück zum Zitat Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396 Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396
43.
46.
Zurück zum Zitat Ferreira MF, Sobrinho LG, Santos MA, Sousa MFF, Uvnäs-Moberg K (1998) Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Psychoneuroendocrinology 23:1005–1013, Medline. doi:10.1016/S0306-4530(98)00063-8 PubMedCrossRef Ferreira MF, Sobrinho LG, Santos MA, Sousa MFF, Uvnäs-Moberg K (1998) Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Psychoneuroendocrinology 23:1005–1013, Medline. doi:10.​1016/​S0306-4530(98)00063-8 PubMedCrossRef
47.
Zurück zum Zitat Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258 Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258
49.
Zurück zum Zitat Wallace RB, Sherman BM, Bean JA (1985) Clinical and biologic antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril 43:726–732, MedlinePubMed Wallace RB, Sherman BM, Bean JA (1985) Clinical and biologic antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril 43:726–732, MedlinePubMed
50.
52.
Zurück zum Zitat Balcioglu A, Wurtman RJ (1998) Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. Int J Obes Relat Metab Disord 22:325–328, Medline. doi:10.1038/sj.ijo.0800589 PubMedCrossRef Balcioglu A, Wurtman RJ (1998) Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. Int J Obes Relat Metab Disord 22:325–328, Medline. doi:10.​1038/​sj.​ijo.​0800589 PubMedCrossRef
55.
Zurück zum Zitat Cavagnini F, Maraschini C, Pinto M, Dubini A, Polli EE (1981) Impaired prolactin secretion in obese patients. J Endocrinol Invest 4:149–153, MedlinePubMed Cavagnini F, Maraschini C, Pinto M, Dubini A, Polli EE (1981) Impaired prolactin secretion in obese patients. J Endocrinol Invest 4:149–153, MedlinePubMed
56.
Zurück zum Zitat Amatruda JM, Hochstein M, Hsu TH, Lockwood DH (1982) Hypothalamic and pituitary dysfunction in obese males. Int J Obes 6:183–189, MedlinePubMed Amatruda JM, Hochstein M, Hsu TH, Lockwood DH (1982) Hypothalamic and pituitary dysfunction in obese males. Int J Obes 6:183–189, MedlinePubMed
57.
Zurück zum Zitat Weaver JU, Noonan K, Kopelman PG, Coste M (1990) Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 32:641–646, MedlineCrossRef Weaver JU, Noonan K, Kopelman PG, Coste M (1990) Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 32:641–646, MedlineCrossRef
58.
Zurück zum Zitat Weaver JU, Noonan K, Kopelman PG (1991) An association between hypothalamic–pituitary dysfunction and peripheral endocrine function in extreme obesity. Clin Endocrinol (Oxf) 35:97–102, MedlineCrossRef Weaver JU, Noonan K, Kopelman PG (1991) An association between hypothalamic–pituitary dysfunction and peripheral endocrine function in extreme obesity. Clin Endocrinol (Oxf) 35:97–102, MedlineCrossRef
60.
Zurück zum Zitat Kopelman PG, Pilkington TRE, White N, Jeffcoate SL (1980) Persistence of abnormal hypothalamic control of prolactin secretion in some obese women after weight reduction. BMJ 281:358–359, MedlinePubMedCrossRef Kopelman PG, Pilkington TRE, White N, Jeffcoate SL (1980) Persistence of abnormal hypothalamic control of prolactin secretion in some obese women after weight reduction. BMJ 281:358–359, MedlinePubMedCrossRef
62.
Zurück zum Zitat Baptista T, Alastre T, Contreras Q et al (1997) Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 30:250–255, MedlinePubMedCrossRef Baptista T, Alastre T, Contreras Q et al (1997) Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 30:250–255, MedlinePubMedCrossRef
63.
Zurück zum Zitat Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834, MedlinePubMed Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834, MedlinePubMed
64.
Zurück zum Zitat Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399–405, Medline. doi:10.1016/0091-3057(87)90340-6 CrossRef Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399–405, Medline. doi:10.​1016/​0091-3057(87)90340-6 CrossRef
65.
Zurück zum Zitat Ling C, Svensson L, Odén B et al (2003) Identification of functional prolactin (PRL] gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804–1808, Medline. doi:10.1210/jc.2002-021137 PubMedCrossRef Ling C, Svensson L, Odén B et al (2003) Identification of functional prolactin (PRL] gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804–1808, Medline. doi:10.​1210/​jc.​2002-021137 PubMedCrossRef
66.
Zurück zum Zitat Hugo ER, Brandebourg TD, Comstock CES, Gersin KS, Sussman JJ, Ben-Jonathan N (2006) LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 147:306–313, Medline. doi:10.1210/en.2005-0989 PubMedCrossRef Hugo ER, Brandebourg TD, Comstock CES, Gersin KS, Sussman JJ, Ben-Jonathan N (2006) LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 147:306–313, Medline. doi:10.​1210/​en.​2005-0989 PubMedCrossRef
67.
Zurück zum Zitat Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM (1998) Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 178:1010–1015, Medline. doi:10.1016/S0002-9378(98)70540-X PubMedCrossRef Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM (1998) Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 178:1010–1015, Medline. doi:10.​1016/​S0002-9378(98)70540-X PubMedCrossRef
69.
71.
Zurück zum Zitat Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390, MedlineCrossRef Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390, MedlineCrossRef
72.
Zurück zum Zitat Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142, MedlinePubMed Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142, MedlinePubMed
73.
Zurück zum Zitat Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726, MedlineCrossRef Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726, MedlineCrossRef
74.
Zurück zum Zitat Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246, MedlinePubMedCrossRef Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246, MedlinePubMedCrossRef
75.
Zurück zum Zitat Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574, MedlinePubMed Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574, MedlinePubMed
76.
Zurück zum Zitat Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26:341–346, MedlinePubMed Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26:341–346, MedlinePubMed
77.
Zurück zum Zitat Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370, Medline Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370, Medline
78.
81.
Zurück zum Zitat Yavuz D, Deyneli O, Akpinar I, et al (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187–193, Medline. doi:10.1530/eje.0.1490187 PubMedCrossRef Yavuz D, Deyneli O, Akpinar I, et al (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187–193, Medline. doi:10.​1530/​eje.​0.​1490187 PubMedCrossRef
82.
Zurück zum Zitat Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554, Medline. doi:10.1210/jc.87.4.1550 PubMedCrossRef Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554, Medline. doi:10.​1210/​jc.​87.​4.​1550 PubMedCrossRef
83.
Zurück zum Zitat Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92:4254–4259, Medline. doi:10.1210/jc.2007-0454 PubMedCrossRef Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92:4254–4259, Medline. doi:10.​1210/​jc.​2007-0454 PubMedCrossRef
87.
88.
Zurück zum Zitat Meier AH, Cincotta AH, Lovell WC (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:248–253, Medline. doi:10.1007/BF01930467 PubMedCrossRef Meier AH, Cincotta AH, Lovell WC (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:248–253, Medline. doi:10.​1007/​BF01930467 PubMedCrossRef
90.
Zurück zum Zitat Kamath V, Jones CN, Yip JC et al (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose. Insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemia women. Diabetes Care 20:1697–1701, Medline. doi:10.2337/diacare.20.11.1697 Kamath V, Jones CN, Yip JC et al (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose. Insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemia women. Diabetes Care 20:1697–1701, Medline. doi:10.​2337/​diacare.​20.​11.​1697
91.
Metadaten
Titel
The effects of hyperprolactinemia on bone and fat
verfasst von
Amal Shibli-Rahhal
Janet Schlechte
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 2/2009
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0097-3

Weitere Artikel der Ausgabe 2/2009

Pituitary 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.